EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liraglutide-Conjugated Poly(methyl vinyl ether- alt -maleic acid)-Coated Core–Shell Upconversion Nanoparticles for Theranostics of Diabetes

Oleksandr Shapoval iD, Hana Engstová, Miroslav Šlouf iD, Olga Kočková iD, Andrea Dlasková, Martin Jabůrek, Aminadav Halili iD, Alexandra Mozheitová, Daniel Jirák iD, Petr Ježek, Daniel Horák iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c11275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Oleksandr Shapoval und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 2, 162 00 Prague 6, Czech Republic. Hauptthemen laut MEDLINE: Nanoparticles, Liraglutide, Theranostic Nanomedicine, Maleates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy, Grantov? Agentura Cesk? Republiky, Ministerstvo Zdravotnictv? Cesk? Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the diagnostics of diabetes, specific targeting of drugs (e.g., liraglutide) to insulin-deficient β-cells with their simultaneous noninvasive imaging is currently needed. In this report, liraglutide (LGL)-conjugated poly(methyl vinyl ether-alt-maleic acid) (PMVEMA)-coated core-shell NaYF4:Yb,Er,Fe@NaYF4:Nd upconversion nanoparticles (CS-UCNPs) have been developed, thoroughly physicochemically characterized, and evaluated in vivo. Novel codoping of Fe2+, Yb3+, and Er3+ ions in the host NaYF4 induced upconversion emission in the red region at both 980 and 808 nm excitation, making the particles suitable for deep-tissue imaging. Surface functionalization with PMVEMA provided colloidal stability and facilitated covalent conjugation with LGL, enabling targeted binding to GLP-1 receptors on pancreatic β-cells, increasing glucose-stimulated insulin secretion from isolated Langerhans islets. Biocompatibility of CS-UCNP@PMVEMA-LGL nanoparticles was confirmed by the trypan blue dye exclusion assay. When the fluorescent dye Flamma was conjugated to the nanoparticles, in vivo fluorescence imaging revealed significantly enhanced accumulation of CS-UCNP@PMVEMA-LGL-Flamma nanoparticles in the pancreas 24 h after intramuscular injection compared with intravenous administration, with luminescence intensity approximately doubled. The improved pancreatic targeting efficiency was attributed to enhanced binding to GLP-1 receptors. Confocal microscopy and elemental analysis confirmed receptor-mediated uptake of the nanoparticles by internalization and their localization within pancreatic β-cells. These findings highlight the potential of CS-UCNP@PMVEMA-LGL nanoparticles as biocompatible targetable imaging agents with future applications in pancreatic diagnostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLiraglutideTheranostic NanomedicineMaleatesDiabetes Mellitus, ExperimentalAnimalsMiceInsulin-Secreting CellsMaleHumansInsulinPolyvinylsFluoridesYttrium

Stichwörter der Autor:innen

Flammadiabetesliraglutidenanoparticlespoly(methyl vinyl ether-alt-maleic acid)theranosticsupconversion

Substanzen

LiraglutideMaleatessodium yttriumtetrafluorideInsulinPolyvinylsFluoridesYttrium

Autor:innen und Institutionen

  • Institute of Macromolecular Chemistry of the Czech Academy of Sciences, Heyrovského nám. 2, 162 00 Prague 6, Czech Republic.
  • Institute of Physiology of the Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague 4, Czech Republic.
  • Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague 4, Czech Republic.
  • Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University, 121 08 Prague 1, Czech Republic.
  • Faculty of Health Studies, Technical University of Liberec, 461 17 Liberec, Czech Republic.

ORCID-Profile: Oleksandr Shapoval, Miroslav Šlouf, Olga Kočková, Aminadav Halili, Daniel Jirák, Daniel Horák

Förderung

  • Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy
  • Grantov? Agentura Cesk? Republiky
  • Ministerstvo Zdravotnictv? Cesk? Republiky
  • NextGenerationEU

Zitieren

APA

Shapoval, O., Engstová, H., Šlouf, M., Kočková, O., Dlasková, A., Jabůrek, M., Halili, A., Mozheitová, A., Jirák, D., Ježek, P., & Horák, D. (2025). Liraglutide-Conjugated Poly(methyl vinyl ether- alt -maleic acid)-Coated Core–Shell Upconversion Nanoparticles for Theranostics of Diabetes. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c11275

Vancouver

Shapoval O, Engstová H, Šlouf M, Kočková O, Dlasková A, Jabůrek M, et al. Liraglutide-Conjugated Poly(methyl vinyl ether- alt -maleic acid)-Coated Core–Shell Upconversion Nanoparticles for Theranostics of Diabetes. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c11275

BibTeX
@article{Shapoval2025,
  author = {Shapoval, Oleksandr and Engstová, Hana and Šlouf, Miroslav and Kočková, Olga and Dlasková, Andrea and Jabůrek, Martin and Halili, Aminadav and Mozheitová, Alexandra and Jirák, Daniel and Ježek, Petr and Horák, Daniel},
  title = {Liraglutide-Conjugated Poly(methyl vinyl ether- alt -maleic acid)-Coated Core–Shell Upconversion Nanoparticles for Theranostics of Diabetes},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c11275}
}
Kostenlos starten →